Business Description
Verve Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US92539P1012
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.23 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.34 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.73 | |||||
Beneish M-Score | 0.65 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -36 | |||||
3-Year EPS without NRI Growth Rate | -25.8 | |||||
3-Year FCF Growth Rate | -23.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 7.62 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.77 | |||||
9-Day RSI | 42.33 | |||||
14-Day RSI | 35.84 | |||||
6-1 Month Momentum % | -53.01 | |||||
12-1 Month Momentum % | -65.04 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 19.82 | |||||
Quick Ratio | 19.82 | |||||
Cash Ratio | 19.38 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.2 | |||||
Shareholder Yield % | -56.24 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1381.45 | |||||
Net Margin % | -1226.43 | |||||
FCF Margin % | -933.87 | |||||
ROE % | -37.6 | |||||
ROA % | -29.63 | |||||
ROIC % | -167.08 | |||||
ROC (Joel Greenblatt) % | -204.8 | |||||
ROCE % | -35.18 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 24.98 | |||||
PB Ratio | 0.77 | |||||
Price-to-Tangible-Book | 0.77 | |||||
EV-to-EBIT | 0.37 | |||||
EV-to-Forward-EBIT | -2.92 | |||||
EV-to-EBITDA | 0.38 | |||||
EV-to-Forward-EBITDA | -3 | |||||
EV-to-Revenue | -5.12 | |||||
EV-to-Forward-Revenue | 0.15 | |||||
EV-to-FCF | 0.64 | |||||
Price-to-Net-Current-Asset-Value | 0.96 | |||||
Price-to-Net-Cash | 0.99 | |||||
Earnings Yield (Greenblatt) % | 270.27 | |||||
FCF Yield % | -33.21 |